FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Merck | AIDS vaccine

Scientists blame adenovirus for AIDS vax trial fiasco

Two years ago the revelation that Merck's experimental AIDS vaccine actually increased the risk of infection among the people who volunteered for a clinical trial proved a serious blow to the whole research field, which it is still recovering from. But now researchers at Imperial College of London believe they have figured out what went wrong.

The scientific team concludes that the adenovirus--a deactivated common cold virus used to deliver the vaccine--triggered an immune response in the volunteers. Their bodies were flooded with CD4 immune cells, which fight the cold. But the same cells are also a favorite target of HIV and play a key role in infecting patients.

"We expected that pre-existing immunity would only render the vaccine less efficacious, and instead it increased the susceptibility of people to HIV," Abel Benlahrech tells Bloomberg. A large scale trial of a new AIDS vaccine in Thailand used a bird virus to deliver the vaccine, avoiding the problems associated with the adenovirus.

- check out the story from Bloomberg

Related Articles:
New data analysis revives AIDS trial controversy
Merck scraps AIDS vaccine
Time to rewrite AIDS vaccine playbook


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Research Email Newsletter:
Be the first to comment
More stories about Merck   AIDS vaccine  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.